Inclusion Criteria:

          1. Age 18 years or older;

          2. Patients with histologically or cytologically confirmed, unresectable advanced solid
             tumors that have progressed despite standard therapy or for which no standard therapy
             exists;

          3. Patients must have at least one measurable lesion as defined by RECIST v1.1;

          4. ECOG performance score 0 or 1;

          5. Life expectancy ≥ 3 months;

          6. Patients who have sufficient Baseline organ function and whose laboratory data meet
             the following criteria at enrollment:

               1. Absolute neutrophil count （ANC）≥1.5 × 109/L;

               2. Platelets ≥100 × 109/L;

               3. Hemoglobin ≥90g/dL;

               4. Liver function:

                  Serum bilirubin ≤1.5 × upper limit of normal (ULN) or ≤ 3×ULN in any subject with
                  Gilbert's Syndrome; Aspartate aminotransferase（AST） and alanine
                  aminotransferase（ALT） ≤2.5 × ULN without liver metastases, or ≤5 × ULN if the
                  patient has documented liver metastases;

               5. International normalization ratio ≤1.2 if the patient is not on anticoagulants,
                  or ≤3 if the patient is on anticoagulants;

               6. Serum creatinine ≤1.5 mg/dL, or estimated glomerular filtration rate (eGFR)≥60
                  mL/min/1.73 m2;

          7. Women of childbearing potential must have a negative serum pregnancy test prior to
             study entry, and agree to use adequate contraception from study entry through at least
             1 month after the last dose of study drug. A female patient of nonchildbearing
             potential will have had at least 12 continuous months of natural (spontaneous)
             amenorrhea, follicle stimulating hormone level ≥40 mIU/mL at Screening, and an
             appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms),
             or have had surgical bilateral oophorectomy, hysterectomy, or tubal ligation ≥6 weeks
             prior to Screening; in the case of oophorectomy alone, reproductive status will be
             confirmed by hormone level assessment;

          8. A male patient must agree to use adequate contraception (male condom with spermicide
             or provide evidence of successful vasectomy; sterile sexual partner; or female sexual
             partner who uses an intrauterine device with spermicide, a female condom with
             spermicide, a contraceptive sponge with spermicide, an intravaginal system, a double
             diaphragm with spermicide, a cervical cap with spermicide) from study entry through at
             least 1 month after the last dose of study drug;

          9. Patients must provide written informed consent prior to any study procedures.

        Exclusion Criteria:

          -  Disease

               1. Patients with symptomatic central nervous system (CNS) metastases or
                  carcinomatous meningitis; Note: Patients with treated CNS metastases may
                  participate in this trial if the patient has completed radiotherapy or surgery
                  for CNS metastases >2 weeks prior to study entry and if the patient is
                  neurologically stable ≥ 2 weeks (no new neurologic deficits from brain metastasis
                  on Screening clinical examination, no new findings on CNS imaging, and no
                  corticosteroids being used).

                  Medical Conditions

               2. Patients who have a history of another primary malignancy, with the exception of
                  locally excised non-melanoma skin cancer and carcinoma in situ of uterine cervix.
                  A patient who has had no evidence of disease from another primary cancer for 3 or
                  more years is allowed to participate in the study;

               3. Patients who have a known history of active hepatitis C or chronic hepatitis B
                  ("active hepatitis" defined as HCV RNA level ≥ 103 copies/mL for hepatitis C or
                  HBV DNA level ≥ 104 copies/mL for hepatitis B at Screening);

               4. Patients who have a known diagnosis of human immunodeficiency virus (HIV);

               5. Patients who have any severe and/or uncontrolled medical conditions or other
                  conditions that, in the opinion of the Investigator and Sponsor, could affect the
                  patient's participation in the study such as:

                    1. Uncontrolled diabetes mellitus, HbA1c≥8%;

                    2. Malignant illnesses that are uncontrolled or whose control may be
                       jeopardized by treatment with this study treatment;

                    3. Moderate or severe hepatic impairment, i.e., Child-Pugh class B or C (see
                       appendix 8.6);

                    4. Autoimmune disorders with systemic therapy;

               6. Patients who with an allo-transplant of any kind (including those with a
                  xenograft heart valve);

               7. Any significant ophthalmologic abnormality, including but not limited to the
                  following:

                    1. Grade 2 or greater severity syndrome of dry eye;

                    2. Keratoconjunctivitis sicca;

                    3. Sjogren's syndrome;

                    4. Iritis;

               8. Patients who have a history of definite neurological disorders that affected
                  brain function activity, including epilepsy or dementia;

               9. Active infections requiring antibiotic intravenous therapy at Screening;

              10. Pregnancy or lactation;

              11. Patients with any comorbid medical disorder that, in the opinion of the
                  Investigator or Sponsor, may increase the risk of toxicity; Organ Function and
                  Laboratory Values

              12. Patients who have impaired cardiac function or clinically significant cardiac
                  diseases, including any of the following:

                    1. Baseline QT interval corrected for heart rate using Fridericia's formula
                       >480 msec or congenital long QT syndrome;

                    2. Concomitant diseases that could prolong the QT interval, as assessed by the
                       Investigator, such as autonomic neuropathy (caused by diabetes or
                       Parkinson's disease), cirrhosis, uncontrolled hypothyroidism, or grade 3 or
                       greater severity electrolyte abnormality (CTCAE v5.0);

                    3. Concomitant medications known to prolong the QT interval;

                    4. History or presence of serious uncontrolled ventricular arrhythmias;

                    5. Left ventricular ejection fraction <50% assessed by echocardiogram;

                    6. Any of the following within 3 months prior to the first dose of study
                       medication: myocardial infarction, severe/unstable angina, coronary artery
                       bypass graft, congestive heart failure, cerebrovascular accident, or
                       transient ischemic attack;

                    7. Other clinically significant heart disease such as congestive heart failure
                       NYHA Class Ⅱ or greater severity and requiring heart transplant or
                       uncontrolled hypertension (systolic blood pressure > 150 mmHg or diastolic
                       blood pressure > 100 mmHg, in spite of antihypertensive medication); Prior
                       Therapy

              13. Chemotherapy, biologic therapy, herbal therapy, radiotherapy or investigational
                  agents within 5 half lives or within 4 weeks (whichever is longer) prior to
                  administration of the first dose of study drug on Day 1 or have not recovered to
                  grade 1 or below from the side effects of such therapy (excluding cases of
                  alopecia);

              14. Patients received potent CYP3A4 inducer or inhibitor within 2 weeks prior to
                  administration of the first dose of study drug on Day 1.

              15. Patients received systemic corticosteroids within 2 weeks prior to administration
                  of the first dose of study drug on Day 1.

              16. Major surgery for any cause within 4 weeks of first dosing;

              17. Treated with immunomodulator (e.g., motolimod, GS9688, IMO4200, E-6742, E-6887,
                  etc).

              18. Patients who have a history of allergic reactions (significant urticaria,
                  angioedema, anaphylaxis) attributed to compounds of similar chemical or biologic
                  composition to DN1508052-01; Patients with scheduled surgeries or who are, in the
                  Investigator's opinion, likely to require surgery.